Effect of a recombinant CD4-IgG on in vitro T helper cell function: Data from a phase I/II study of patients with AIDS

Mario Clerici, Robert Yarchoan, Stephen Blatt, Craig Hendrix, Arthur J. Ammann, Samuel Broder, Gene M. Shearer

Research output: Contribution to journalArticle

Abstract

Ten patients with AIDS were enrolled in a phase I/II protocol of recombinant CD4-IgG (rCD4-IgG) treatment. Patients' peripheral blood leukocytes (PBL) were tested before, during, and after therapy with rCD4-IgG for T helper (TH) cell function assessed by antigen- and mitogen-stimulated proliferation and interleukin-2 production in response to influenza A virus, allogeneic PBL (alloantigens), and phytohemagglutinin. Although clinical benefit was not evident, rCD4-IgG treatment was associated with rapid and potent improved TH cell function for two of three stimuli tested in 90% of the patients. These data are complemented by an in vitro experimental model that demonstrates the opposing immunologic effects of rgp120 and rCD4-IgG on TH cell function of PBL from uninfected individuals. Thus, restoration of TH cell function by rCD4-IgG in the absence of increased CD4 cell counts could be due to removal of an immunosuppressive factor, possibly gp120. These findings suggest that rCD4-IgG can induce partial restoration of immune function in AIDS patients, even in the absence of apparent short-term clinical benefit.

Original languageEnglish (US)
Pages (from-to)1012-1016
Number of pages5
JournalJournal of Infectious Diseases
Volume168
Issue number4
Publication statusPublished - Oct 1993
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Clerici, M., Yarchoan, R., Blatt, S., Hendrix, C., Ammann, A. J., Broder, S., & Shearer, G. M. (1993). Effect of a recombinant CD4-IgG on in vitro T helper cell function: Data from a phase I/II study of patients with AIDS. Journal of Infectious Diseases, 168(4), 1012-1016.